

Massimo Serra

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7536005/massimo-serra-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

116
papers

5,518
citations

44
h-index

71
g-index

117
ext. papers

6,167
ext. citations

6.6
avg, IF

5.04
L-index

#	Paper	IF	Citations
116	miR-486-5p expression is regulated by DNA methylation in osteosarcoma.. <i>BMC Genomics</i> , 2022 , 23, 142	4.5	1
115	Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2).. <i>Cancer</i> , 2022 ,	6.4	1
114	Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies. <i>Cancers</i> , 2021 , 13,	6.6	12
113	Impact of ABC Transporters in Osteosarcoma and Ewing's Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?. <i>Cells</i> , 2021 , 10,	7.9	2
112	Long-Term Follow-up of a Randomized Study of Oral Etoposide versus Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse. <i>Sarcoma</i> , 2020 , 2020, 8260730	3.1	3
111	Characterization of water-soluble esters of nitrobenzoxadiazole-based GSTP1-1 inhibitors for cancer treatment. <i>Biochemical Pharmacology</i> , 2020 , 178, 114060	6	4
110	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. <i>JAMA Oncology</i> , 2020 , 6, 724-734	13.4	60
109	Cisplatin Resistance in Osteosarcoma: Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments. <i>Frontiers in Oncology</i> , 2020 , 10, 331	5.3	18
108	ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma. <i>Cells</i> , 2020 , 9,	7.9	13
107	Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
106	Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6
105	Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors. <i>Cells</i> , 2020 , 9,	7.9	14
104	Biology of Osteosarcomas 2020 , 213-215		
103	Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. <i>Cancer Letters</i> , 2019 , 456, 29-39	9.9	26
102	Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 299-311	5.5	8
101	An update on emerging drugs in osteosarcoma: towards tailored therapies?. <i>Expert Opinion on Emerging Drugs</i> , 2019 , 24, 153-171	3.7	25
100	Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. <i>Cellular and Molecular Life Sciences</i> , 2019 , 76, 609-625	10.3	32

99	Establishment and characterization of in vivo orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and NSG mice. <i>Cancer Medicine</i> , 2018 , 7, 665-676	4.8	7
98	Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines. <i>Cancer Letters</i> , 2018 , 433, 18-32	9.9	17
97	Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. <i>International Journal of Cancer</i> , 2018 , 142, 1594-1601	7.5	19
96	Functionalized Keratin as Nanotechnology-Based Drug Delivery System for the Pharmacological Treatment of Osteosarcoma. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	21
95	Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?. <i>Expert Review of Molecular Diagnostics</i> , 2018 , 18, 947-961	3.8	9
94	Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?. <i>Future Oncology</i> , 2017 , 13, 673-677	3.6	18
93	Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 245-257	5.5	12
92	Polymorphisms of genes related to metotrexate response and toxicity in high-grade osteosarcoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 123	5.5	2
91	Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients. <i>Pharmacogenomics</i> , 2016 , 17, 2097-2114	2.6	16
90	Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells. <i>PLoS ONE</i> , 2016 , 11, e0166233	3.7	18
89	Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma. <i>Oncotarget</i> , 2016 , 7, 61970-61987	3.3	26
88	Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1 can Overcome Drug Resistance in Osteosarcoma. <i>Current Cancer Drug Targets</i> , 2016 , 16, 261-74	2.8	35
87	H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 4881-9	8.3	35
86	Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2640-2652	6.1	57
85	A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. <i>Cancer Discovery</i> , 2015 , 5, 920-31	24.4	71
84	Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 1449-63	5.5	19
83	An update on chemotherapy for osteosarcoma. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2727-36	4	147
82	Advances in emerging drugs for osteosarcoma. <i>Expert Opinion on Emerging Drugs</i> , 2015 , 20, 495-514	3.7	67

81	Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy. <i>Histopathology</i> , 2015 , 67, 338-47	7.3	15
80	Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy. <i>BMC Medical Genomics</i> , 2014 , 7, 4	3.7	43
79	An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. <i>BMC Cancer</i> , 2014 , 14, 137	4.8	10
78	Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. <i>Investigational New Drugs</i> , 2014 , 32, 1167-80	4.3	22
77	Copy number alterations and neoplasia-specific mutations in MELK, PDCD1LG2, TLN1, and PAX5 at 9p in different neoplasias. <i>Genes Chromosomes and Cancer</i> , 2014 , 53, 579-88	5	13
76	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014 , 23, 6616-33	5.6	77
75	Biology of Osteosarcoma 2014 , 185-188		
74	IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. <i>BMC Cancer</i> , 2013 , 13, 245	4.8	62
73	Genome-wide association study identifies two susceptibility loci for osteosarcoma. <i>Nature Genetics</i> , 2013 , 45, 799-803	36.3	156
72	Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines. <i>Molecular BioSystems</i> , 2012 , 8, 994-1006		57
71	Modulation of the osteosarcoma expression phenotype by microRNAs. <i>PLoS ONE</i> , 2012 , 7, e48086	3.7	226
70	miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. <i>Journal of Pathology</i> , 2012 , 226, 796-805	9.4	113
69	Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. <i>Clinical Cancer Research</i> , 2012 , 18, 432-41	12.9	80
68	Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma. <i>PLoS ONE</i> , 2012 , 7, e48262	3.7	75
67	Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. <i>European Journal of Cancer</i> , 2011 , 47, 1258-66	7.5	43
66	Targeting Glutathione-S Transferase Enzymes in Musculoskeletal Sarcomas: A Promising Therapeutic Strategy. <i>Analytical Cellular Pathology</i> , 2011 , 34, 131-145	3.4	18
65	Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. <i>Laboratory Investigation</i> , 2011 , 91, 1195-205	5.9	130
64	Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 575-86	7.4	64

63	mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts. <i>BMC Medical Genomics</i> , 2011 , 4, 66	3.7	27
62	Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 291-306	5	19
61	Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. <i>Clinical Cancer Research</i> , 2011 , 17, 2110-9	12.9	271
60	Emerging drugs for high-grade osteosarcoma. <i>Expert Opinion on Emerging Drugs</i> , 2010 , 15, 615-34	3.7	81
59	Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. <i>Genes Chromosomes and Cancer</i> , 2010 , 49, 40-51	5	124
58	Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone--an array comparative genomic hybridization study. <i>Genes Chromosomes and Cancer</i> , 2010 , 49, 132-43	5	14
57	Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). <i>International Journal of Cancer</i> , 2010 , 126, 41-52	7.5	27
56	Prognostic Relevance of CCN3 in Bone Sarcomas 2010 , 223-243		
55	Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2209-16	2.2	93
54	Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. <i>Genes Chromosomes and Cancer</i> , 2009 , 48, 289-309	5	41
53	LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 2009 , 48, 679-93	5	68
52	Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. <i>Clinical Cancer Research</i> , 2009 , 15, 3550-6	12.9	56
51	Caveolins in the development and diseases of musculoskeletal system. <i>Cancer Letters</i> , 2009 , 284, 113-219.9		7
50	P53 oncosuppressor influences selection of genomic imbalances in response to ionizing radiations in human osteosarcoma cell line SAOS-2. <i>International Journal of Radiation Biology</i> , 2008 , 84, 591-601	2.9	6
49	Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. <i>Annals of Oncology</i> , 2008 , 19, 1500-1508	10.3	36
48	Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. <i>Cancer Research</i> , 2008 , 68, 6661-8	10.1	96
47	Prognostic value of CCN3 in osteosarcoma. <i>Clinical Cancer Research</i> , 2008 , 14, 701-9	12.9	54
46	Prognostic value of P-glycoprotein in high-grade osteosarcoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4858-60; author reply 4860-1	2.2	13

45	Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. <i>Cancer Research</i> , 2007 , 67, 7675-85	10.1	73
44	Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma. <i>Oncology Reports</i> , 2007 , 18, 1427-34	3.5	4
43	CD99 acts as an oncosuppressor in osteosarcoma. <i>Molecular Biology of the Cell</i> , 2006 , 17, 1910-21	3.5	50
42	Malignant fibrous histiocytoma of bone: analysis of genomic imbalances by comparative genomic hybridisation and C-MYC expression by immunohistochemistry. <i>European Journal of Cancer</i> , 2006 , 42, 1172-80	7.5	37
41	May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol 2006 , 29, 1459		8
40	May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. <i>International Journal of Oncology</i> , 2006 , 29, 1459-68	1	19
39	Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. <i>European Journal of Cancer</i> , 2005 , 41, 1349-61	7.5	109
38	4-Demethoxy-3-deamino-3-saziridinyl-4-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients. <i>European Journal of Cancer</i> , 2005 , 41, 2184-95	7.5	8
37	In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. <i>Oncogene</i> , 2005 , 24, 4349-61	9.2	83
36	Gene amplifications in osteosarcoma-CGH microarray analysis. <i>Genes Chromosomes and Cancer</i> , 2005 , 42, 158-63	5	91
35	Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. <i>Cancer Research</i> , 2005 , 65, 3868-76	10.1	252
34	Genetic analysis of fibrosarcoma of bone, a rare tumour entity closely related to osteosarcoma and malignant fibrous histiocytoma of bone. <i>European Journal of Cell Biology</i> , 2004 , 83, 483-91	6.1	19
33	Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. <i>International Journal of Cancer</i> , 2004 , 108, 358-66	7.5	55
32	Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. <i>Journal of Clinical Oncology</i> , 2003 , 21, 536-42	2.2	86
31	Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. <i>European Journal of Cell Biology</i> , 2003 , 82, 483-93	6.1	34
30	C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1952-60	2.2	65
29	Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. <i>International Journal of Cancer</i> , 2002 , 101, 11-6	7.5	86
28	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. <i>Cancer Gene Therapy</i> , 2002 , 9, 296-307	5.4	95

27	Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21. <i>Oncogene</i> , 2002 , 21, 2261-9	9.2	50
26	The expression of <i>ccn3</i> (nov) gene in musculoskeletal tumors. <i>American Journal of Pathology</i> , 2002 , 160, 849-59	5.8	93
25	Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. <i>Clinical Cancer Research</i> , 2002 , 8, 3893-903	12.9	36
24	Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. <i>Clinical Cancer Research</i> , 2001 , 7, 1790-7	12.9	84
23	Prognostic significance of nuclear accumulation of c-myc and mdm2 proteins in synovial sarcoma of the extremities. <i>Oncology</i> , 2000 , 58, 253-60	3.6	12
22	Identification of EWS/FLI-1 transcripts in giant-cell tumor of bone. <i>International Journal of Cancer</i> , 2000 , 87, 328-35	7.5	18
21	Murine model for skeletal metastases of Ewing's sarcoma. <i>Journal of Orthopaedic Research</i> , 2000 , 18, 959-66	3.8	21
20	Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. <i>Cancer Genetics and Cytogenetics</i> , 2000 , 123, 128-32		55
19	The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. <i>American Journal of Pathology</i> , 2000 , 157, 2123-31	5.8	64
18	The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. <i>Oncogene</i> , 1999 , 18, 739-46	9.2	29
17	P-glycoprotein subcellular localization and cell morphotype in MDR1 gene-transfected human osteosarcoma cells. <i>Biology of the Cell</i> , 1999 , 91, 17-28	3.5	21
16	Redundancy of autocrine loops in human osteosarcoma cells. <i>International Journal of Cancer</i> , 1999 , 80, 581-8	7.5	69
15	Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma. <i>Cancer Genetics and Cytogenetics</i> , 1998 , 100, 106-10		63
14	Genetic imbalances in 67 synovial sarcomas evaluated by comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 1998 , 23, 213-219	5	40
13	Retinoblastoma Susceptibility Gene Product Retrieval in Formalin-fixed, Paraffin-embedded Tissue: A Heating Method for Enhancing Immunohistochemical Staining.. <i>Acta Histochemica Et Cytochemica</i> , 1998 , 31, 193-196	1.9	1
12	Ki-67 Antigen Retrieval in Formalin- or Ethanol-fixed, Paraffin-embedded Tissues: An Enhancement Method for Immunohistochemical Staining with Autoclave Treatment.. <i>Acta Histochemica Et Cytochemica</i> , 1997 , 30, 251-255	1.9	4
11	Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor. <i>Human Pathology</i> , 1996 , 27, 408-16	3.7	87
10	Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities. <i>Cytotechnology</i> , 1996 , 19, 253-6	2.2	5

9	Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. <i>New England Journal of Medicine</i> , 1995 , 333, 1380-5	59.2	331
8	Clinical relevance of Ki-67 expression in bone tumors. <i>Cancer</i> , 1995 , 75, 806-14	6.4	78
7	New model for bone resorption study in vitro: human osteoclast-like cells from giant cell tumors of bone. <i>Journal of Bone and Mineral Research</i> , 1994 , 9, 1013-20	6.3	37
6	Pre-treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin. <i>International Journal of Cancer</i> , 1994 , 58, 95-101	7.5	15
5	Evaluation of osteonectin as a diagnostic marker of osteogenic bone tumors. <i>Human Pathology</i> , 1992 , 23, 1326-31	3.7	28
4	Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992 , 119, 121-6	4.9	11
3	Establishment and characterization of a primitive neuroectodermal tumor of bone continuous cell line (LAP-35). <i>International Journal of Cell Cloning</i> , 1990 , 8, 409-24		24
2	Giant Cell Tumor of Bone: A Model for the in Vitro Human Osteoclast Characterization. <i>Tumori</i> , 1989 , 75, 389-395	1.7	5
1	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells		1